AGF Management Ltd. Has $121.40 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

AGF Management Ltd. cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 574,143 shares of the medical research company’s stock after selling 1,030 shares during the quarter. AGF Management Ltd. owned about 0.31% of IQVIA worth $121,397,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. MGO One Seven LLC increased its holdings in shares of IQVIA by 35.1% during the 2nd quarter. MGO One Seven LLC now owns 4,788 shares of the medical research company’s stock worth $1,012,000 after acquiring an additional 1,243 shares during the last quarter. Headlands Technologies LLC acquired a new position in shares of IQVIA during the 2nd quarter worth approximately $1,090,000. Malaga Cove Capital LLC acquired a new position in shares of IQVIA during the 2nd quarter worth approximately $248,000. Daiwa Securities Group Inc. increased its holdings in shares of IQVIA by 1.0% during the 2nd quarter. Daiwa Securities Group Inc. now owns 35,823 shares of the medical research company’s stock worth $7,574,000 after acquiring an additional 366 shares during the last quarter. Finally, LGT Fund Management Co Ltd. increased its holdings in shares of IQVIA by 724.3% during the 2nd quarter. LGT Fund Management Co Ltd. now owns 25,059 shares of the medical research company’s stock worth $5,298,000 after acquiring an additional 22,019 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Price Performance

Shares of IQV stock opened at $235.20 on Wednesday. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The company has a market cap of $42.85 billion, a P/E ratio of 32.13, a P/E/G ratio of 2.29 and a beta of 1.49. The business has a fifty day simple moving average of $236.12 and a 200 day simple moving average of $234.48.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The business had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. During the same period in the prior year, the company earned $2.22 EPS. IQVIA’s revenue for the quarter was up 2.3% on a year-over-year basis. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of research reports. Robert W. Baird upped their price objective on IQVIA from $235.00 to $251.00 and gave the company a “neutral” rating in a report on Tuesday, July 23rd. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a report on Thursday, September 5th. Argus raised IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Morgan Stanley upped their price objective on IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. Finally, Jefferies Financial Group lowered IQVIA from a “buy” rating to a “hold” rating and decreased their price objective for the company from $266.00 to $242.00 in a report on Wednesday, July 24th. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $266.67.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. The sale was disclosed in a filing with the SEC, which is available through this link. 1.60% of the stock is owned by corporate insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.